Companies / SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc.
Nasdaq: SABSCIK 1833214MIAMI BEACH, FL
Financials · FY2025
Ownership
91.0M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 0.05% | 43,296 |
| Institutions | 59.74% | 54,356,314 |
| Public float | 40.21% | 36,586,758 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 7
View all →| Insider | % of shares | Shares |
|---|---|---|
Kropotova AlexandraCHIEF MEDICAL OFFICER | 0.05% | 43,296 |
Bausch Christoph LawrenceCHIEF OPERATING OFFICER | — | — |
Jain RitaDirector | — | — |
Reich Samuel JCEOCEO · Director | — | — |
Sullivan Eddie JoePRESIDENT · Director | — | — |
To LucySee Remarks | — | — |
Zaccardelli DavidDirector | — | — |
Institutional holders 58
View all →| Holder | Value | % of shares |
|---|---|---|
| $42.71M | 12.55% | |
| $24.63M | 7.07% | |
| $16.86M | 4.84% | |
| $16.46M | 4.84% | |
| $14.40M | 4.13% | |
| $13.04M | 3.74% | |
| $11.96M | 3.37% | |
| $11.62M | 3.33% | |
| $10.66M | 3.13% | |
| $8.22M | 2.42% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | Kropotova Alexandra Executive | Other | Common Stock | — | -988 -2.23% | 43,296 0.05% of shares | low |
| Feb 3, 2026 | Sullivan Eddie Joe Executive | Grant | Stock option (right to buy) | — | +3.0M | 3,000,000 3.30% of shares | low |
| Feb 3, 2026 | Reich Samuel J CEO | Grant | Stock option (right to buy) | — | +4.8M | 4,800,000 5.28% of shares | low |
| Feb 3, 2026 | Bausch Christoph Lawrence Executive | Grant | Stock option (right to buy) | — | +1.8M | 1,800,000 1.98% of shares | low |
| Feb 3, 2026 | Kropotova Alexandra Executive | Grant | Stock option (right to buy) | — | +2.4M | 2,400,000 2.64% of shares | low |
| Feb 3, 2026 | To Lucy Executive | Grant | Stock option (right to buy) | — | +2.4M | 2,400,000 2.64% of shares | low |
| Jan 5, 2026 | Jain Rita Director | Grant | Stock Option (right to buy) | — | +240K | 240,000 0.26% of shares | low |
| Jan 5, 2026 | Zaccardelli David Director | Grant | Stock Option (right to buy) | — | +240K | 240,000 0.26% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Perceptive Advisors LLC | Passive13G | — |
| RTW Investments, LP | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| Balyasny Asset Management L.P. | Passive13G | — |
| Perceptive Advisors LLC | Passive13G/A | — |
| Millennium Management LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| SABS | — | 78397T202 |